Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking and Simulation Studies of Flavanone and its Derived Compounds on PI3K-AKT Pathway Targeting against Cancer

Author(s): Sagar Nagare, Kiran Bharat Lokhande and K. Venkateswara Swamy*

Volume 20, Issue 1, 2023

Published on: 18 October, 2022

Article ID: e260522205302 Pages: 9

DOI: 10.2174/1570163819666220526150152

Price: $65

Abstract

Background: Flavanone compounds and their related derivatives are reported in controlling cell cycle, angiogenesis, and metastasis. Phosphoinositide 3-kinases is a major drug target.

Methods: Crystalize structure of Phosphoinositide 3-kinases-Akt complex obtained from Protein Data Bank (PDBID: 3CQW) was selected as receptor protein and the binding site has been identified with PDBSum Database. Flavanone and its derivatives were retrieved using freely available existing drug databases like Drug Bank, Zinc, and PubChem. New derivatives were modified by altering the flavanone at Beta ring position. This modification would help in maintaining stable structural conformation and retaining better anticancer activity. Retrieved Flavanone derivatives from the drug database were docked against 3CQW Protein with the advanced docking tool FlexX. MD simulations of the best molecule were performed with the Desmond package by calculating nonbonding interactions such as electrostatic interaction and hydrogen bond stable and favorable conformations were calculated.

Results: These interaction studies would help identify new potential drug candidates with the help of computer-aided drug designing techniques.

Conclusion: Natural chemicals have received a lot of attention because of their vast range of applications in human health and disease prevention without creating any negative side effects. Molecular docking is an essential approach for drug development since it allows for effective screening of potential therapeutics in a short time. We hypothesized in this paper that natural flavanone and its derivatives may be effective as Akt-1 inhibitors.

Keywords: Flavanones, docking, molecular modeling, cancer, phosphoinositide, cell cycle.

Graphical Abstract

[1]
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7(8): 606-19.
[http://dx.doi.org/10.1038/nrg1879] [PMID: 16847462]
[2]
Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5(12): 921-9.
[http://dx.doi.org/10.1038/nrc1753] [PMID: 16341083]
[3]
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2(7): 489-501.
[http://dx.doi.org/10.1038/nrc839] [PMID: 12094235]
[4]
Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phos-phoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96(8): 4240-5.
[http://dx.doi.org/10.1073/pnas.96.8.4240] [PMID: 10200246]
[5]
Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6(3): 184-92.
[http://dx.doi.org/10.1038/nrc1819] [PMID: 16453012]
[6]
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploit-ing the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12): 988-1004.
[http://dx.doi.org/10.1038/nrd1902] [PMID: 16341064]
[7]
Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67(1): 481-507.
[http://dx.doi.org/10.1146/annurev.biochem.67.1.481] [PMID: 9759495]
[8]
Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 2006; 281(15): 9977-86.
[http://dx.doi.org/10.1074/jbc.M512502200] [PMID: 16476736]
[9]
Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, Stephens L. p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase. Curr Biol 2005; 15(6): 566-70.
[http://dx.doi.org/10.1016/j.cub.2005.02.020] [PMID: 15797027]
[10]
Chang JD, Sukhova GK, Libby P, et al. Deletion of the phos-phoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA 2007; 104(19): 8077-82.
[http://dx.doi.org/10.1073/pnas.0702663104] [PMID: 17483449]
[11]
Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modu-lates the cardiac response to chronic pressure overload by distinct kinasedependent and independent effects. Cell 2004; 118(3): 375-87.
[http://dx.doi.org/10.1016/j.cell.2004.07.017] [PMID: 15294162]
[12]
Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14(5): 381-95.
[http://dx.doi.org/10.1016/S0898-6568(01)00271-6] [PMID: 11882383]
[13]
Lowe HIC, Toyang NJ, Watson CT, Ayeah KN, Bryant J. HLBT-100: A highly potent anti-cancer flavanone from Tillandsia recurvata (L.) L. Cancer Cell Int 2017; 17(1): 38.
[http://dx.doi.org/10.1186/s12935-017-0404-z] [PMID: 28286420]
[14]
Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Water-field MD. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17(1): 615-75.
[http://dx.doi.org/10.1146/annurev.cellbio.17.1.615] [PMID: 11687500]
[15]
Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261(3): 470-89.
[http://dx.doi.org/10.1006/jmbi.1996.0477] [PMID: 8780787]
[16]
Fowler ZL, Shah K, Panepinto JC, Jacobs A, Koffas MA. Development of non-natural flavanones as antimicrobial agents. PLoS One 2011; 6(10)e25681
[http://dx.doi.org/10.1371/journal.pone.0025681] [PMID: 22039419]
[17]
Ali TE-S. Synthesis and fungicidal activity of some new 4h-chromen-4-ones containing some 1,3-thiazole, 1,3-thiazine, 1,2,4-triazole and 1,2,4-triazine moieties. Phosphorus Sulfur Silicon Relat Elem 2007; 182(8): 1717.
[http://dx.doi.org/10.1080/10426500701313896]
[18]
Murti Y, Mishra P. Synthesis and evaluation of flavanones as anticancer agents. Indian J Pharm Sci 2014; 76(2): 163-6.
[PMID: 24843190]
[19]
Joseph L, George M, Kassaye G. One pot method for the synthesis of arylidene flavanones and some of its activities. Afr J Clin Exp Microbiol 2008; 9(3)
[http://dx.doi.org/10.4314/ajcem.v9i3.7499]
[20]
Lippa B, Pan G, Corbett M, et al. Synthesis and structure based optimization of novel Akt inhibitors. Bioorg Med Chem Lett 2008; 18(11): 3359-63.
[http://dx.doi.org/10.1016/j.bmcl.2008.04.034] [PMID: 18456494]
[21]
Bowers KJ, Chow E, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the ACM/IEEE Conference on Supercompu-ting (SC06). Tampa, Florida. 2006, November 11-17;
[http://dx.doi.org/10.1109/SC.2006.54]
[22]
UniProt Consortium T. UniProt: The universal protein knowledgebase. Nucleic Acids Res 2018; 46(5): 2699.
[http://dx.doi.org/10.1093/nar/gky092] [PMID: 29425356]
[23]
Laskowski RA. Jabłońska J, Pravda L, Vařeková R S, Thornton J M. PDBsum: Structural summaries of PDB en-tries. Protein Sci 2018; 27(1): 129-34.
[http://dx.doi.org/10.1002/pro.3289]
[24]
Lokhande K, Nawani N. K Venkateswara S, Pawar S. Bifla-vonoids from Rhus succedanea as probable natural inhibi-tors against SARS-CoV-2: A molecular docking and molecu-lar dynamics approach. J Biomol Struct Dyn 2020; 1-13.
[http://dx.doi.org/10.1080/07391102.2020.1858165] [PMID: 33300454]
[25]
Lokhande KB, Doiphode S, Vyas R, Swamy KV. Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. J Biomol Struct Dyn 2021; 39(18): 7294-305.
[http://dx.doi.org/10.1080/07391102.2020.1805019] [PMID: 32815481]

Rights & Permissions Print Cite
Article Metrics
37
2
© 2024 Bentham Science Publishers | Privacy Policy